Great example of why Comms must have a role in strategic decisions, not just to advise on how to navigate the downstream impacts, and not to help figure out a "better answer", but to have the authority and credibility to say, "We cannot do this."
This will haunt Twitch for years
#FierceBiotechSummit continues! @VergeGenomics CMO, Diego Cadavid, joined a panel on a massively important topic: How AI is and will revolutionize drug discovery and development. #client
Interim clinical data on MRT-2359 demonstrated favorable tolerability, PK & PD profiles. MRT-2359 has been observed to significantly reduce GSPT1 protein levels in patient tumors and has shown evidence of tumor size reductions. CEO @Markus_Warmuth comments:
Today, we are celebrating two milestones, including interim data from our Phase 1/2 trial of MRT-2359. We believe the results, the first ever to show clinical activity of a rationally designed #moleculargluedegrader in solid tumors, represent an important advance for the field.
It was wonderful celebrating @Apnimed’s inclusion in the #Fierce15 last evening.
Apnimed is pursuing a simple but profound challenge: transforming the treatment of obstructive sleep apnea with the first oral therapy for the condition. #FierceBiotechSummit#client
Our Head of Media & Thought Leadership, Adam Silverstein, will join hundreds of #biotechnology professionals in Boston for two major conferences, #FierceBiotechSummit and #STATSummit.
Watch this space for insights and reflections, and follow him at @a_silverstein.
Mike Nally, CEO of @generate_biomed, explains how the company is leveraging computation to accelerate the pace of drug discovery and development. More from his interview at #JPM23 here: https://t.co/ZCLhIUUEzj #FlagshipJPM
Adrian Gottschalk, CEO of @FoghornTX, describes the pipeline progress expected in the year ahead for Forghorn's oncology-focused portfolio. More from his interview at #JPM23 here: https://t.co/MDlltPzCsb #FlagshipJPM
📽️ @generate_biomed's @mike_nally helps me wrap my human brain around how AI and machine learning might impact drug development in the future. It's a buzzy area, I'm trying to learn the substance behind it. #JPM23
#JPM23 is underway. We asked execs at early-stage #biotech companies what’s on their mind. Read what they said and our view on why strategic communication is poised to help in the face of headwinds: https://t.co/B9Cbob6iiR
The story of how a relatively obscure Japanese drug company created, after 25 years of failure, the first drug that can slow Alzheimer’s, with help from a Swedish scientist & some begrudging cash from Biogen
From @adamfeuerstein, @damiangarde and me
https://t.co/EYOKX0lODt
"It was always my hope that, as a scientist, I could make some contributions that would benefit human health."
Listen to our conversation with 2022 chemistry laureate @CarolynBertozzi, where she shares why she wanted to become a scientist and the importance of chemistry:
Hear from our CEO, @mike_nally, about our strategic research agreement w/ @Amgen that combines their expertise in engineering protein-based therapies w/ our unique #machinelearning enabled drug generation platform. https://t.co/eiX7AJ44Xg #AI#generativebiology#innovation
We’re excited to introduce Laronde and Endless RNA, a new, synthetic RNA that is an emerging class of programmable medicines, essential for human health. #RNA#startup#innovation@FlagshipPioneer https://t.co/Am88wgwkAY